FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021.
REUTERS/Mike Segar(Reuters) - Eli Lilly and Co has received a subpoena from the U.S. Department of Justice related to its New Jersey plant that makes its COVID-19 treatment, the drugmaker said in a filing on Thursday.
Lilly said it had previously engaged external counsel to conduct an independent investigation of certain allegations relating to the Branchburg plant.
“Lilly is deeply committed to manufacturing high-quality medicines for patients who need them, and the safety and quality of our products is our highest priority,” the company said.
Reuters reported earlier this month that the company’s employees have accused a factory executive of altering documents required by government regulators in an effort to downplay serious quality control problems at the manufacturing site in Branchburg, New Jersey.
Eli Lilly, Mike Segar, Lilly, “ Lilly
Company, REUTERS, U.S . Department of Justice, Reuters, U.S . Food, Drug Administration
Branchburg , New Jersey, New Jersey